Home › FTC sues AbbVie, Teva over testosterone replacement therapy deal
 

Keywords :   


FTC sues AbbVie, Teva over testosterone replacement therapy deal

2014-09-09 11:55:23| Biotech - Topix.net

The Federal Trade Commission filed a complaint Monday against AbbVie and Teva Pharmaceutical Industries alleging the companies illegally blocked American consumers' access to lower-cost versions of the testosterone replacement therapy AndroGel. According to the FTC complaint, AbbVie of Chicago and its partner Besins Healthcare Inc. allegedly filed baseless patent infringement lawsuits against potential generic competitors to delay the introduction of lower-priced versions of AndroGel, which generates more than $1 billion a year in annual sales.

Tags: deal therapy replacement sues

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
05.11NI rise hits workers harder than employers, says OBR
05.11Tropical Storm Rafael Graphics
05.11Tropical Storm Rafael Wind Speed Probabilities Number 8
05.11Tropical Storm Rafael Public Advisory Number 8
05.11Summary for Tropical Storm Rafael (AT3/AL182024)
05.11Tropical Storm Rafael Forecast Advisory Number 8
05.11Lenzing Expands Nonwovens Range
05.11Netflix Europe offices raided in tax fraud probe
More »